Literature DB >> 18037296

Contribution of DNA repair mechanisms to determining chemotherapy response in high-grade glioma.

Jonathon F Parkinson1, Helen T Wheeler, Kerrie L McDonald.   

Abstract

Despite the existence of a well described, succinct pathological grading system for gliomas, tumour behaviour between individual patients varies widely. In addition, predictors of response to treatment in glioblastoma multiforme are lacking. The majority of chemotherapeutic agents currently employed exert their effect on DNA. As our understanding of DNA repair mechanisms improves and predictive markers are elucidated, this may allow treating clinicians to individualise treatment based on molecular markers. This review examines important DNA repair mechanisms and their application to glioblastoma multiforme. By improving understanding of these mechanisms, and particularly the variations that occur between tumours and individuals, it may be possible to adapt treatment to maximise effectiveness and minimise toxicity.

Entities:  

Mesh:

Year:  2007        PMID: 18037296     DOI: 10.1016/j.jocn.2007.06.005

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  7 in total

1.  BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening.

Authors:  Jie Ding; Shaofang Wu; Chen Zhang; Arnav Garyali; Emmanuel Martinez-Ledesma; Feng Gao; Adarsha Pokkulandra; Xiaolong Li; Christopher Bristow; Alessandro Carugo; Dimpy Koul; Wk Alfred Yung
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

2.  Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide.

Authors:  Ana P Montaldi; Elza T Sakamoto-Hojo
Journal:  Clin Exp Med       Date:  2012-07-25       Impact factor: 3.984

Review 3.  Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.

Authors:  Abigail Tattersall; Neil Ryan; Alison J Wiggans; Ewelina Rogozińska; Jo Morrison
Journal:  Cochrane Database Syst Rev       Date:  2022-02-16

Review 4.  O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.

Authors:  Marta Brell; Javier Ibáñez; Avelina Tortosa
Journal:  BMC Cancer       Date:  2011-01-26       Impact factor: 4.430

5.  KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis.

Authors:  Seon Rang Woo; Yunhee Ham; Wonyoung Kang; Heekyoung Yang; Sujong Kim; Juyoun Jin; Kyeung Min Joo; Do-Hyun Nam
Journal:  Biomed Res Int       Date:  2014-09-10       Impact factor: 3.411

Review 6.  Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma.

Authors:  Laura Annovazzi; Marta Mellai; Davide Schiffer
Journal:  Cancers (Basel)       Date:  2017-05-26       Impact factor: 6.639

7.  Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development.

Authors:  Dorine A Bax; Suzanne E Little; Nathalie Gaspar; Lara Perryman; Lynley Marshall; Marta Viana-Pereira; Tania A Jones; Richard D Williams; Anita Grigoriadis; Gilles Vassal; Paul Workman; Denise Sheer; Rui M Reis; Andrew D J Pearson; Darren Hargrave; Chris Jones
Journal:  PLoS One       Date:  2009-04-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.